Status | Study |
Recruiting |
Study Name: Ofatumumab With High Dose Methylprednisone Followed by Ofatumumab and Alemtuzumab in 17p CLL Condition: CLL SLL Date: 2011-10-18 Interventions: Drug: Ofatumumab 1000 mg IV |
Recruiting |
Study Name: Subcutaneous Alemtuzumab Combined With Oral Dexamethasone, Followed by Alemtuzumab Maintenance or Allo-SCT in CLL With 17p- or Refractory to Fludarabine Condition: Chronic Lymphocytic Leukemia Date: 2011-06-28 Interventions: Drug: Alemtuzumab Alemtuzumab 30 mg s.c. 3 × weekly for 28 days (Days 1, 3, 5; 8, 10, 12; etc.) |
Recruiting |
Study Name: Treatment Strategies for Children With Smith-Magenis Syndrome Condition: Developmental Delay Disorders Chromosome Deletion Mental R Date: 2007-07-21 Interventions: Drug: dTR Melatonin (NIH CC PDS) Device: P |
Recruiting |
Study Name: Natural History Study of Smith-Magenis Syndrome Condition: Chromosome Abnormalities Smith Magenis Syndrome Date: 2001-03-20 |